Maricann Group (CNSX:MARI – Free Report) had its target price hoisted by Raymond James from $6.00 to $6.50 in a research report report published on Tuesday, BayStreet.CA reports.
Separately, Canaccord Genuity Group dropped their price objective on shares of Maricann Group from $6.50 to $6.00 and set a speculative buy rating for the company in a research note on Friday, January 12th.
Get Our Latest Report on Maricann Group
Maricann Group Price Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Featured Articles
- Five stocks we like better than Maricann Group
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Stocks Leading the U.S. Agriculture Comeback
- The 3 Best Blue-Chip Stocks to Buy Now
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How to Buy Cheap Stocks Step by Step
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.